Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Guillermo Montalban-Bravo, Nicholas J. Short, Kelly S. Chien, Yesid Alvarado Valero, Naval Daver, Gautam Borthakur, Mahesh Swaminathan, Abhishek Maiti, Danielle E. Hammond, Graciela Nogueras-Gonzalez, Xuelin Huang, Heather Schneider, Kristen Shelly, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2023-178035

Published: 2023

Journal Articles

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Georgina Gener-Ricos, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G. Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia-Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2023-187795

Published: 2023

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Lucia Masarova, Hagop M. Kantarjian, Naveen Pemmaraju, Hussein A Abbas, Prithviraj Bose, Mahesh Swaminathan, Sherry Pierce, Koji Sasaki, Musa Yilmaz, Nicholas J. Short, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Maro Ohanian, Kapil N. Bhalla, Courtney D. DiNardo, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2023-187968

Published: 2023

Journal Articles

A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/ Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Mai M M Aly, Mahesh Swaminathan, Katherine G. Akers, Seongho Kim, Harry Ramos, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian

Blood (2021) 138 (Supplement 1): 1249.

https://doi.org/10.1182/blood-2021-148902

Published: 2021

Journal Articles

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Mahesh Swaminathan, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Wendy Walinski, Meriem Said, Stephanie Halliwell, Claire Puff, Kristopher Attwood, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2021-151636

Published: 2021

Journal Articles

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Mahesh Swaminathan, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Wendy Walinski, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 4426.

https://doi.org/10.1182/blood-2021-152947

Published: 2021

Journal Articles

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Abhay Singh Singh, Nuria Mencia-Trinchant, Elizabeth A. Griffiths, Mahesh Swaminathan, Matthew Gravina, Rutaba Tajammal, Mark G. Faber, Marc S. Ernstoff, LunBiao Yan, Eti Sinha, Megan M. Herr, Duane C Hassane, Monica L. Guzman, Amanda Przespolewski, Eunice S. Wang, Swapna Thota

Blood (2021) 138 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2021-150347

Published: 2021

Journal Articles

Efficacy Analysis of Different FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients - a Systematic Review and Meta-Analysis

Mahesh Swaminathan, Mai M M Aly, Katherine G. Akers, Seongho Kim, Harry Ramos, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian

Blood (2021) 138 (Supplement 1): 1225.

https://doi.org/10.1182/blood-2021-154098

Published: 2021

Journal Articles

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Manu Pandey, MBBS, Mahesh Swaminathan, MBBS, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amanda Przespolewski, DO, Swapna Thota, MD, Jeffrey Baron, PharmD, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3866.

https://doi.org/10.1182/blood-2019-132123

Published: 2019

Journal Articles

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Kelly S. Chien, MD, Mahesh Swaminathan, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Nicholas J. Short, MD, Kelly Soltysiak, PhD, Sherry A. Pierce, BSN, BA, Jane Waukau, BSN, RN, Darla Miller, Jorge E. Cortes, MD, Yesid Alvarado, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4252.

https://doi.org/10.1182/blood-2019-129226

Published: 2019

Journal Articles

Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity

Blood (2018) 132 (Supplement 1): 5240.

https://doi.org/10.1182/blood-2018-99-117287

Published: 2018

Journal Articles

RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia

Mahesh Swaminathan, MD, Nicholas Stavrou, Spiraggelos Antzoulatos, Maher Albitar, MD, Keyur Patel, MD PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MD MSc, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 5113.

https://doi.org/10.1182/blood-2018-99-119098

Published: 2018

Journal Articles

Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia

Mahesh Swaminathan, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD MSc, Marina Y. Konopleva, MD PhD, Zeev E. Estrov, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Sherry A. Pierce, BSN, BA, MD Emogene Dellasala, BS, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3013.

https://doi.org/10.1182/blood-2018-99-119914

Published: 2018

Journal Articles

Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities

Prajwal Boddu, MD, Mahesh Swaminathan, MD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Nitin Jain, MD, Naveen Pemmaraju, MD, Jeffrey L. Jorgensen, MD PhD, Sa A. Wang, MD, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Tapan Kadia, MD

Blood (2017) 130 (Supplement 1): 1419.

https://doi.org/10.1182/blood.V130.Suppl_1.1419.1419

Published: 2017

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, MD, Hagop M. Kantarjian, MD, Naval Daver, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Tapan Kadia, MD, Courtney D. DiNardo, MDMSc, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD, Farhad Ravandi, MBBS, Maria Rhona Pinsoy, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 723.

https://doi.org/10.1182/blood.V130.Suppl_1.723.723

Published: 2017

NARROW

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/ Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Efficacy Analysis of Different FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients - a Systematic Review and Meta-Analysis

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity

RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia

Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia

Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only